Navigation Links
NOVAVAX Announces Positive Results for the Second Phase II Clinical Trial of its Trivalent Seasonal Influenza Virus-like Particle (VLP) Vaccine Candidate
Date:9/1/2009

4-fold or higher rise in HAI titer from baseline) ranged from 81-86% for H3N2, 57-66% for H1N1, and 62-67% for B for subjects with and without existing antibody before vaccination. As seen in Novavax's previous seasonal flu vaccine study, robust HAI responses were also observed against drifted H3N2 strains, demonstrating the potential for VLP vaccines to be cross-protective against flu viruses from different seasons without the addition of an adjuvant.

One of the main advantages of Novavax's recombinant, cell culture based VLP technology is that it results in VLPs that are a genetic match to the flu strains of interest. It does not require live flu virus seed that has to be adapted to grow in eggs to create the egg-based vaccine. This attribute of recombinant VLPs may lead to a more efficacious vaccine against the flu strains that are circulating in the community. The results of this study provided Novavax's first human data to support this hypothesis. The H3N2 strain that was circulating during the 2008-2009 season did not grow well in eggs; therefore, an adapted or "substitute" strain had to be used to make the egg-based influenza vaccines, including Fluzone(R), the same egg-based vaccine used in this study. Recipients of Novavax's VLP vaccine had higher antibody responses against the H3N2 virus that was circulating in the community than recipients of Fluzone(R). The number of subjects that were studied was too small to draw definitive conclusions, but the results strongly support moving forward with larger head-to-head trials of the VLP and egg-based vaccines, the first of which is scheduled to start this Fall in elderly adults.

"The safety and immunogenicity results from this study give us confidence to move our seasonal influenza VLP vaccine candidate forward into late phase development," said Dr. Penny Heaton, Chief Medical Officer and Vice President of Development of Novavax. "Given the immunogenicity results we s
'/>"/>

SOURCE Novavax, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. NOVAVAX Virus-Like Particle Vaccine Protects Against 2009 Pandemic H1N1 Influenza Virus
2. Novavax Reports Second Quarter 2009 Financial Results
3. Novavax Announces Appointment of Frederick W. Driscoll as Vice President, Chief Financial Officer and Treasurer
4. Novavax Announces Release Date of 2009 Second Quarter, Financial Results and Investor Conference Call
5. Novavax Announces Selection of a Respiratory Syncytial Virus Vaccine Candidate for Advanced Preclinical Studies
6. Novavax Announces Appointment of John J. Trizzino as Senior Vice President, International and Government Alliances
7. Novavax Announces Repayment of $5 Million of Convertible Debt
8. Cadila Pharmaceuticals Launches Joint Venture With Novavax in India
9. Spanish Government Selects Novavaxs VLP Technology for Comprehensive Flu Vaccine Solution in Spain
10. Novavax Appoints Stanley Erck to Board of Directors
11. Preclinical Proof-of-Concept Studies Published for Novavax Seasonal Influenza Virus-Like-Particle Vaccine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... England , January 15, 2014 A ... win races on the Formula 1 track could help to ... McLaren Applied Technologies (MAT), Stowhealth (a GP surgery based in ... by healthcare provider Simplyhealth. Telemetry technology, which is ...
(Date:1/15/2014)... VA (PRWEB) January 15, 2014 Two ... have continued their sponsorship of an annual competition for ... in, and access to, innovative STEM study. The competition ... TEAMS: Tests of Engineering Aptitude, Mathematics, and Sciences ...
(Date:1/15/2014)... DTS Language Services, Inc . is pleased to ... Science organizations who need document translations. Clients will now ... documents in advance with a selection of nearly 50 life ... a critical factor in clinical and scientific fields, and decrease ...
(Date:1/15/2014)... Sunnyvale, CA (PRWEB) January 15, 2014 ... throughput research solutions, today announced that Lupin Limited, one ... of Freeslate’s CM Protégé PharmD System for ... in Mumbai, India, is focused on a wide range ...
Breaking Biology Technology:Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 2Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 3Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 4Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 2Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 3Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 4Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 5DTS Improves Efficiency for Life Science Document Translations 2Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 2Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 3
... , Jan. 26 The following is a ... PharmAthene, regarding the Commission on the Prevention of Weapons of ... Card by the Commission on the Prevention of Weapons of ... America still remains vulnerable to bioterrorism.  Our Nation,s ability to ...
... , , TUALATIN, Ore. ... Bulletin Board: WYNX), a platform company dedicated to the ... announced that it has reached an agreement with British-based ... second generation Gas Quality Inferential Measurement Device (GasPT2). , ...
... Jan. 26 /PRNewswire-FirstCall/ - YM BioSciences Inc. (NYSE ... that it may now enroll patients at US clinical sites ... lead product, nimotuzumab. One of the two trials is in ... treatment and being treated palliatively and the other in patients ...
Cached Biology Technology:Waytronx Announces Agreement for Development and Production of Its GASPT2 Device With UK-Based Ingenion Design Limited 2Waytronx Announces Agreement for Development and Production of Its GASPT2 Device With UK-Based Ingenion Design Limited 3Waytronx Announces Agreement for Development and Production of Its GASPT2 Device With UK-Based Ingenion Design Limited 4YM BioSciences announces FDA clearance for two ongoing Phase II nimotuzumab trials into USA 2YM BioSciences announces FDA clearance for two ongoing Phase II nimotuzumab trials into USA 3YM BioSciences announces FDA clearance for two ongoing Phase II nimotuzumab trials into USA 4YM BioSciences announces FDA clearance for two ongoing Phase II nimotuzumab trials into USA 5
(Date:7/9/2014)... New Rochelle, NY, July 9, 2014Biofuels derived from the ... alternative to fossil fuels. To achieve this goal, optimization ... as in open pond systems, is needed. Sapphire Energy ... contamination of open pond algae cultivation systems, described in ... Ann Liebert, Inc., publishers. The article is available on ...
(Date:7/9/2014)... a University of Guelph scientist that involved fitting ... exposure to a neonicotinoid pesticide hampers bees, ability ... Nigel Raine, a professor in Guelph,s School of ... London was published July 9 in the British ... The study shows how long-term pesticide exposure affects ...
(Date:7/9/2014)... A new study shows that some shark species may be ... that may come with rising temperatures. , The Arctic today ... but it wasn,t always like that. Roughly 53 to 38 ... epoch, the Arctic was more similar to a huge temperate ... life, including ancestors of tapirs, hippo-like creatures, crocodiles and giant ...
Breaking Biology News(10 mins):Controlling contamination in open algae ponds for biofuels 2Bee foraging chronically impaired by pesticide exposure: Study 2Shark teeth analysis provides detailed new look at Arctic climate change 2Shark teeth analysis provides detailed new look at Arctic climate change 3
... researchers have identified the job of one of the ... puzzled scientists because it is present in nearly every ... and yet, in laboratory experiments, its function has remained ... enigmatic enzyme known as DinB DNA polymerase is specialized ...
... have identified a handful of microRNAs (miRNAs) that appear ... platelets ?blood cells critical to the body's ability to ... of these same miRNAs, when acting abnormally, may contribute ... that a specific set of miRNA genes are turned ...
... and slow developing gills appear to be keys to ... fish whose adults thrive in icy waters because of ... are important, researchers at the University of Illinois atUrbana-Champaign ... species of notothenioids that inhabit the Ross Sea at ...
Cached Biology News:Common enzyme is a key player in DNA repair 2Common enzyme is a key player in DNA repair 3MiRNA fingerprint identified in platelet formation 2Thin tough skin, slow-growing gills protect larval Antarctic fish 2Thin tough skin, slow-growing gills protect larval Antarctic fish 3
Rabbit polyclonal to Aortic Elastin ( Abpromise for all tested applications). entrezGeneID: 2006 SwissProtID: P15502...
Rabbit polyclonal to GPR56 ( Abpromise for all tested applications). entrezGeneID: 9289 SwissProtID: Q9Y653...
Mouse monoclonal [2A4] to Cytokeratin 8 + 18 + 19 ( Abpromise for all tested applications). Antigen: Cytokeratins isolated from cultured pig kidney epithelial cells. Entrez GeneID: 3856 S...
Feline Rhinotracheitis Virus...
Biology Products: